Cryo-Cell International Sees Revenue Dip and Net Loss in Fiscal 2025 What does a year of financial downturn mean for the world’s first private cord blood bank? Cryo-Cell International, Inc. a pioneer in cord blood and cord tissue cryopreservation, has…
New Data Show Potential for Twice-Yearly Dosing, Enhancing Treatment Options for HIV Patients Why is the current landscape of HIV treatment ripe for innovation? ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as…
Strategic License Agreement Advances Novel Compounds for Autoimmune Diseases Why are autoimmune diseases still a significant challenge for pharmaceutical companies? Asahi Kasei Pharma, a global leader in drug development, is taking a decisive step to address this issue. By entering…
Ionis Poised for Continued Growth with Multiple Upcoming Therapeutic Launches Is the biotech industry ready for a new wave of transformative therapies? Ionis Pharmaceuticals, a leader in RNA-targeted therapies, reported robust financial results and significant pipeline advancements for the year…
IQVIA Strengthens Early-Stage Discovery Research with Advanced In Vitro and AI-Driven Solutions Why is the life sciences industry facing a critical need for accelerated drug discovery? IQVIA Holdings Inc. a global leader in advanced analytics, technology solutions, and clinical research…
Clinical-Stage Biotech Zura Bio Seeks to Raise Capital for Innovative Therapies In the competitive landscape of biotechnology, where innovation and capital are paramount, Zura Bio Limited (Nasdaq: ZURA) stands out as a company dedicated to developing novel and differentiated medicines…
Vir Biotechnology Seeks to Raise $200 Million in Public Offering In the competitive landscape of biopharmaceutical innovation, where securing capital is crucial for advancing groundbreaking treatments, Vir Biotechnology, Inc. stands out. The company, focused on harnessing the immune system to…
Positive Opinion Paves Way for Phase III Trial of Acetylleucine in Rare Neurological Conditions Why are rare neurological disorders often overlooked in drug development? IntraBio Inc., an Austin, Texas-based global biopharmaceutical company, is addressing this gap by advancing a potential treatment…
Veracyte Showcases Over 15 Abstracts Highlighting Decipher and TrueMRD Genomic Tests What if genomic tests could revolutionize the way we treat urologic cancers? Veracyte, Inc. a leading cancer diagnostics company, is making significant strides in this direction. The company will…
Gossamer Bio Reports Mixed Results for Seralutinib in PAH, Demonstrates Strong Efficacy in High-Risk Subgroups Is the current landscape of pulmonary arterial hypertension (PAH) treatments failing to meet the needs of high-risk patients? Gossamer Bio, Inc. a biopharmaceutical company focused…
Merck Evolves Structure to Enhance Commercial Execution and Portfolio Growth In an industry where the pace of innovation and market dynamics are constantly evolving, how can pharmaceutical companies ensure they stay ahead? Merck known as MSD outside of the United…
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis Takeda today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer…
